Dare Bioscience Inc (DARE): Next-Year EPS Estimate 49.30%
As of 2026-05-20, Dare Bioscience Inc (DARE) has a next-year EPS growth estimate of 49.30%. Featured in 2 EPS revision reports, most recently on 2026-04-20.
On 2026-05-19, analyst consensus for DARE's next-year EPS growth shifted from 45.45% to 49.30% — a positive change of 3.85 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at 21.11%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 49.30%
- EPS growth this year
- 21.11%
- EPS next quarter (est)
- -$0.30
- Last price
- $2.33
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-05-20 | 49.30% | 21.11% | -$0.30 | $2.33 |
| 2026-05-19 | 49.30% | 21.11% | -$0.30 | $2.25 |
| 2026-05-18 | 45.45% | 20.56% | -$0.31 | $2.11 |
| 2026-05-17 | 45.45% | 20.56% | -$0.31 | $2.17 |
| 2026-05-14 | 51.24% | -0.83% | -$0.30 | $2.86 |
| 2026-05-13 | 51.24% | -0.83% | -$0.30 | $2.82 |
| 2026-05-12 | 51.24% | -0.83% | -$0.30 | $2.63 |
| 2026-05-11 | 51.24% | -0.83% | -$0.30 | $2.52 |
| 2026-05-10 | 51.24% | -0.83% | -$0.30 | $2.75 |
| 2026-05-07 | 51.24% | -0.83% | -$0.30 | $2.91 |
| 2026-05-06 | 51.24% | -0.83% | -$0.30 | $3.16 |
| 2026-05-05 | 51.24% | -0.83% | -$0.30 | $3.27 |
| 2026-05-04 | 51.24% | -0.83% | -$0.30 | $3.11 |
| 2026-05-03 | 51.24% | -0.83% | -$0.30 | $2.34 |
| 2026-04-30 | 51.24% | -0.83% | -$0.30 | $2.28 |
| 2026-04-29 | 51.24% | -0.83% | -$0.30 | $2.10 |
| 2026-04-28 | 51.24% | -0.83% | -$0.30 | $2.19 |
| 2026-04-27 | 51.24% | -0.83% | -$0.30 | $2.24 |
| 2026-04-26 | 51.24% | -0.83% | -$0.30 | $2.11 |
| 2026-04-24 | 51.24% | -0.83% | -$0.30 | $2.11 |
| 2026-04-23 | 51.24% | -0.83% | -$0.30 | $2.12 |
| 2026-04-22 | 51.24% | -0.83% | -$0.30 | $2.27 |
| 2026-04-21 | 51.24% | -0.83% | -$0.30 | $2.36 |
| 2026-04-20 | 51.24% | -0.83% | -$0.30 | $2.87 |
| 2026-04-19 | 51.24% | -0.83% | -$0.30 | $2.95 |
| 2026-04-16 | 51.24% | -0.83% | -$0.30 | $2.72 |
| 2026-04-15 | 51.24% | -0.83% | -$0.30 | $1.79 |
| 2026-04-14 | 51.24% | -0.83% | -$0.30 | $1.75 |
| 2026-04-13 | 51.24% | -0.83% | -$0.30 | $1.78 |
| 2026-04-12 | 51.24% | -0.83% | -$0.30 | $1.83 |
Reports Featuring DARE
Recent News
- Dare Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved TherapiesGlobeNewswire
- Dare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Strategic Milestones and Financial ...GuruFocus.com
- Dare Bioscience Reports Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Dare Bioscience Inc (DARE) Q4 2025 Earnings Report Preview: What To ExpectGuruFocus.com
Screen Performance
Aggregate stats across all 1713 tickers our top-EPS-revision screen has flagged over the past 49 days.
- Median return since detection
- +2.8%
- % of tickers in the green
- 58%
- Median return on winners
- +15.1%
- Large revisions captured
- 630
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Dare Bioscience Inc's next-year EPS growth estimate?▾
As of 2026-05-20, Dare Bioscience Inc (DARE) has a next-year EPS growth estimate of 49.30%, based on analyst consensus.
When was the latest EPS estimate revision for DARE?▾
The most recent revision occurred on 2026-05-19, when analysts adjusted the next-year EPS growth estimate from 45.45% to 49.30%.
What sector and industry does Dare Bioscience Inc belong to?▾
Dare Bioscience Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. DARE appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Dare Bioscience Inc (DARE) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports